Personalized rheumatic medicine through dose reduction reduces the cost of biological treatment – a retrospective intervention analysis-Reference-Cited by-同舟云学术

Personalized rheumatic medicine through dose reduction reduces the cost of biological treatment – a retrospective intervention analysis

Published:2019-07-19 Issue:5 Volume:48 Page:398-407
ISSN:0300-9742
Container-title:Scandinavian Journal of Rheumatology
language:en
Short-container-title:Scandinavian Journal of Rheumatology

Author:

Meyer MK¹²³⁴⁵,Andersen M¹²³,Ring T³⁶⁷,Andersen GN¹²⁴,Ehlers LH⁷,Rasmussen C¹²⁵⁷,Stensballe A³

Affiliation:

1. Department of Rheumatology, North Denmark Regional Hospital, Hjoerring, Denmark

2. Center for Clinical Science, Aalborg University, Aalborg, Denmark

3. Department of Health Science and Technology, Aalborg University, Aalborg, Denmark

4. Center for Clinical Research, North Denmark Regional Hospital, Hjoerring, Denmark

5. The DANBIO Registry and Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre of Head and Orthopedics, Rigshospitalet, Glostrup, Denmark

6. Department of Clinical Medicine, Aalborg University, Aalborg, Denmark

7. Department of Health Economics and Management, Aalborg University, Aalborg, Denmark

Publisher

Informa UK Limited

Subject

Immunology,General Medicine,Immunology and Allergy,Rheumatology

Link

https://www.tandfonline.com/doi/pdf/10.1080/03009742.2019.1585940

Reference46 articles.

1. The immunopathogenesis of seropositive rheumatoid arthritis: from triggering to targeting

2. Managing rheumatic and musculoskeletal diseases — past, present and future

3. Impact of Infliximab and Etanercept Biosimilars on Biological Disease-Modifying Antirheumatic Drugs Utilisation and NHS Budget in the UK

4. AMGROS. Official market surveilance report 2016, in Danish (http://www.amgros.dk/media/45781/amgros-markedsovervaagning-4-kvt-2016-public.pdf). Accesssed 11 July 2018.

5. Two-year results of disease activity score (DAS)-remission-steered treatment strategies aiming at drug-free remission in early arthritis patients (the IMPROVED-study)

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Two‐year results of tapered dupilumab for CRSwNP demonstrates enduring efficacy established in the first 6 months;Allergy;2023-07-02

2. Interval prolongation of etanercept in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a randomized controlled trial;Scandinavian Journal of Rheumatology;2022-03-02

3. Protein array-based companion diagnostics in precision medicine;Expert Review of Molecular Diagnostics;2020-12-01

4. Viewpoint on Time Series and Interrupted Time Series Optimum Modeling for Predicting Arthritic Disease Outcomes;Current Rheumatology Reports;2020-05-20